Background-Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients.Methods-Retrospective chart review of (n = 23) inpatients with opioid use disorder or opioid dependence due to chronic pain.Results-Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety-six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post-discharge.Discussion and Conclusions-Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms.
Many major psychiatric illnesses have been associated with excessive and prolonged release of glucocorticoid stress hormones potentially leading to deleterious neuronal effects. Recent studies have suggested that oxidative stress is associated with psychiatric illnesses. Oxidative stress is an overproduction of reactive oxygen species (ROS) that overwhelms the cellular antioxidant capacity. The mitochondria are responsible for most oxygen consumption and are a major source of ROS production. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase also contributes significantly to ROS production. This study aims to elucidate the effects of glucocorticoids on oxidative damage to protein, mitochondrial function, NADPH oxidase activity, and antioxidant capacity. Rat pheochromocytoma PC12 cells were treated with corticosterone at concentrations of 0.031, 0.063, and 0.125 mmol/l for 24 h. Protein carbonylation, activities of mitochondrial complex I and III, activity of NADPH oxidase, total antioxidant capacity, and activities of superoxide dismutase (SOD) and catalase (CAT) were analyzed. We found that chronic treatment with corticosterone increased the amount of protein carbonylation in PC12 cells. Complex I activity was decreased with corticosterone treatment, while no change was seen in complex III activity or NADPH oxidase activity. Total antioxidant capacity was increased at the lowest dosage level tested. Although corticosterone treatment had no effect on CAT activity, corticosterone at the highest dosage significantly decreased SOD activity. These results suggest that excessive glucocorticoid activity can increase oxidative damage to protein, possibly by inhibiting activities of mitochondrial complex I and antioxidant enzyme SOD.
ObjectiveElectroconvulsive therapy is effective in treatment-resistant schizophrenia (TRS) but use is limited due to stigma and concerns around cognitive adverse effects. Magnetic seizure therapy (MST) is a promising new neuromodulation technique that uses transcranial magnetic stimulation to induce therapeutic seizures. Studies of MST in depression have shown clinical improvement with a favorable adverse effect profile. No studies have examined the clinical utility of MST in schizophrenia.MethodsWe conducted an open-label pilot clinical trial of MST in eight TRS patients. Up to 24 MST treatments were delivered depending on treatment response. We assessed clinical outcome through the Brief Psychiatric Rating Scale (BPRS) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Cognitive testing included a neuropsychological test battery, the Autobiographical Memory Inventory (AMI), Montreal Cognitive Assessment (MoCA), and reorientation time.ResultsFour patients completed the trial as per protocol. For all patients and for trial completers alone, there was a significant clinical and quality of life improvement. Three met pre-determined criteria for remission (total score ≤25 on the BPRS) and one met criteria for response (i.e., ≥25% BPRS improvement from baseline for two consecutive assessments). Pre and post neurocognitive data showed no significant cognitive adverse effects apart from a decrease in AMI scores.ConclusionIn this pilot study, MST demonstrated evidence for feasibility in patients with TRS, with promise for clinical efficacy and negligible cognitive side effects. Further study in larger clinical populations is needed.Clinical Trial Registration, Identifier NCT01596608.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.